These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38885690)

  • 1. Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action.
    Anderson M; Towse A; Outterson K; Mossialos E
    Lancet Microbe; 2024 Jun; ():. PubMed ID: 38885690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards mission-driven investment in new antimicrobials? What role for Chinese strategic industrial financing vehicles in responding to the challenge of antimicrobial resistance?
    Husain L; Hu Y; Huang Y
    Global Health; 2024 Mar; 20(1):26. PubMed ID: 38532478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Will the EU Clinical Trials Regulation Support the Innovative Industry in Bringing New Medicines Faster to Patients?
    Atzor S; Gokhale S; Doherty M
    Pharmaceut Med; 2013 Apr; 27(2):75-82. PubMed ID: 23585715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Facilitators and Barriers to the Implementation of Incentives for Antibiotic Access and Innovation.
    Årdal C; Lacotte Y; Edwards S; Ploy MC; On Behalf Of The European Union Joint Action On Antimicrobial Resistance And Healthcare-Associated Infections Eu-Jamrai
    Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34205554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
    Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and opportunities for incentivising antibiotic research and development in Europe.
    Anderson M; Panteli D; van Kessel R; Ljungqvist G; Colombo F; Mossialos E
    Lancet Reg Health Eur; 2023 Oct; 33():100705. PubMed ID: 37546576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To Push or To Pull? In a Post-COVID World, Supporting and Incentivizing Antimicrobial Drug Development Must Become a Governmental Priority.
    Cama J; Leszczynski R; Tang PK; Khalid A; Lok V; Dowson CG; Ebata A
    ACS Infect Dis; 2021 Aug; 7(8):2029-2042. PubMed ID: 33606496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multilevel Governance and Shared Sovereignty: European Union, Member States, and the FCTC.
    Mamudu HM; Studlar DT
    Governance (Oxf); 2009 Jan; 22(1):73-97. PubMed ID: 20622934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Implementation status of Regulation EU 536/2014 in the member states].
    Stahl E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Aug; 60(8):836-840. PubMed ID: 28638933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing the transferability of occupational safety and health economic incentive schemes between different countries.
    Elsler D; Eeckelaert L
    Scand J Work Environ Health; 2010 Jun; 36(4):325-31. PubMed ID: 20526536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revision of the EU Bathing Water Directive: economic costs and benefits.
    Georgiou S; Bateman IJ
    Mar Pollut Bull; 2005 Apr; 50(4):430-8. PubMed ID: 15823305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union.
    Beattie S;
    Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in addressing the market failure of new antimicrobials: Learnings from NICE's subscription-style payment model.
    Schurer M; Patel R; van Keep M; Horgan J; Matthijsse S; Madin-Warburton M
    Front Med Technol; 2023; 5():1010247. PubMed ID: 36860906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of Compassionate Use Programs in the European Union member states.
    Balasubramanian G; Morampudi S; Chhabra P; Gowda A; Zomorodi B
    Intractable Rare Dis Res; 2016 Nov; 5(4):244-254. PubMed ID: 27904819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Global Health Policies of the EU and its Member States: A Common Vision?
    Steurs L; Van de Pas R; Delputte S; Orbie J
    Int J Health Policy Manag; 2018 May; 7(5):433-442. PubMed ID: 29764107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients' Rights in Cross-border Healthcare (Directive 2011/24/EU) and How It Applies to Turkey as a Negotiating Candidate Country.
    Ekmekci PE
    Eur J Health Law; 2017; 24(4):432-444. PubMed ID: 29203967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mid-Term Assessment of the EU Drugs Strategy 2013-2020 and Final Evaluation of the Action Plan on Drugs 2013-2016: Final report.
    Emilie B; Matthew D; Emma D; Cristina Gonzalez M; Stephen H; Stijn H; Kristy K; Martin S; Jirka T
    Rand Health Q; 2018 Jan; 7(2):4. PubMed ID: 29416944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prices and cross-border cigarette purchases in the EU: evidence from demand modelling.
    Stoklosa M
    Tob Control; 2020 Jan; 29(1):55-60. PubMed ID: 30545966
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.